Phase 2 HIV and AIDS Trial, Recruiting (NCT07143968)

Phase 2 HIV and AIDS Trial, Recruiting NCT07143968 Sponsor: Naga P. Chalasani Condition: HIV and AIDS

Printed from Voxsanity (voxsanity.com.au) — NCT07143968 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hiv Aids

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years of age or older and have a confirmed HIV diagnosis
You have been diagnosed with a specific type of liver fat disease (called MASLD), confirmed by an ultrasound, CT scan, MRI, or liver biopsy within the past 12 months
A specific MRI scan shows that at least 8% of your liver is made up of fat
Liver scans show specific levels of liver stiffness and fat buildup that meet the trial's measurements (confirm with trial site)
Your HIV has been well controlled (very low levels of HIV in your blood) for at least 6 months while on HIV treatment
You have been on the same HIV treatment for at least 3 months before joining and have no plans to change it during the study
You are willing to take part in the study

Who may not be able to join:

You have a history of drinking more than an average of 2 alcoholic drinks per day (for men) or 1 per day (for women) for 3 or more months in the past 5 years
You have or have had another type of liver disease, such as autoimmune liver disease, hepatitis B, or hepatitis C (within the past 3 years), or certain inherited liver conditions
You have previously had a liver transplant
Scans or a biopsy suggest you have advanced liver scarring (cirrhosis) or high blood pressure in the liver
Certain liver-related blood test results changed significantly between two early study visits (confirm with trial site)
You are unable to have an MRI scan (for example, due to a pacemaker or severe claustrophobia)
You have poorly controlled type 2 diabetes, based on a specific blood test result (HbA1c above 9.5%)
Certain blood test results at screening are outside the acceptable range, including liver enzyme levels, bilirubin, platelet count, kidney function, blood clotting, or protein levels (confirm with trial site for exact values)
A liver stiffness scan shows results above a certain level, suggesting more advanced liver disease (confirm with trial site)
There are additional eligibility requirements not listed here — confirm all criteria directly with the trial site

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13172786200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07143968

Sponsor: Naga P. Chalasani

Phase: Phase 2

Status: Recruiting

Condition: HIV and AIDS

Trial contact: 13172786200

More information: https://clinicaltrials.gov/study/NCT07143968

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years of age or older and have a confirmed HIV diagnosis
You have been diagnosed with a specific type of liver fat disease (called MASLD), confirmed by an ultrasound, CT scan, MRI, or liver biopsy within the past 12 months
A specific MRI scan shows that at least 8% of your liver is made up of fat
Liver scans show specific levels of liver stiffness and fat buildup that meet the trial's measurements (confirm with trial site)
Your HIV has been well controlled (very low levels of HIV in your blood) for at least 6 months while on HIV treatment
You have been on the same HIV treatment for at least 3 months before joining and have no plans to change it during the study
You are willing to take part in the study

Who may not be able to join:

You have a history of drinking more than an average of 2 alcoholic drinks per day (for men) or 1 per day (for women) for 3 or more months in the past 5 years
You have or have had another type of liver disease, such as autoimmune liver disease, hepatitis B, or hepatitis C (within the past 3 years), or certain inherited liver conditions
You have previously had a liver transplant
Scans or a biopsy suggest you have advanced liver scarring (cirrhosis) or high blood pressure in the liver
Certain liver-related blood test results changed significantly between two early study visits (confirm with trial site)
You are unable to have an MRI scan (for example, due to a pacemaker or severe claustrophobia)
You have poorly controlled type 2 diabetes, based on a specific blood test result (HbA1c above 9.5%)
Certain blood test results at screening are outside the acceptable range, including liver enzyme levels, bilirubin, platelet count, kidney function, blood clotting, or protein levels (confirm with trial site for exact values)
A liver stiffness scan shows results above a certain level, suggesting more advanced liver disease (confirm with trial site)
There are additional eligibility requirements not listed here — confirm all criteria directly with the trial site

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Naga P. Chalasani

Registry

ClinicalTrials.gov

Start date

23 April 2026

Est. completion

1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in hepatic fat content at week 24

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov